TY - JOUR
T1 - Research priorities towards precision antibiotic therapy to improve patient care
AU - Bulman, Zackery P.
AU - Wicha, Sebastian G.
AU - Nielsen, Elisabet I.
AU - Lenhard, Justin R.
AU - Nation, Roger L.
AU - Theuretzbacher, Ursula
AU - Derendorf, Hartmut
AU - Tängdén, Thomas
AU - Zeitlinger, Markus
AU - Landersdorfer, Cornelia B.
AU - Bulitta, Jürgen B.
AU - Friberg, Lena E.
AU - Li, Jian
AU - Tsuji, Brian T.
AU - on behalf of the International Society of Anti-Infective Pharmacology, European Society of Clinical Microbiology and Infectious Diseases Pharmacokinetics and Pharmacodynamics of Anti-Infectives Study Group, and the International Society of Antimicrobial C
N1 - Publisher Copyright:
© 2022 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY-NC-ND 4.0 license
PY - 2022/10
Y1 - 2022/10
N2 - Antibiotic resistance presents an incessant threat to our drug armamentarium that necessitates novel approaches to therapy. Over the past several decades, investigation of pharmacokinetic and pharmacodynamic (PKPD) principles has substantially improved our understanding of the relationships between the antibiotic, pathogen, and infected patient. However, crucial gaps in our understanding of the pharmacology of antibacterials and their optimal use in the care of patients continue to exist; simply attaining antibiotic exposures that are considered adequate based on traditional targets can still result in treatment being unsuccessful and resistance proliferation for some infections. It is this salient paradox that points to key future directions for research in antibiotic therapeutics. This Personal View discusses six priority areas for antibiotic pharmacology research: (1) antibiotic-pathogen interactions, (2) antibiotic targets for combination therapy, (3) mechanistic models that describe the time-course of treatment response, (4) understanding and modelling of host response to infection, (5) personalised medicine through therapeutic drug management, and (6) application of these principles to support development of novel therapies. Innovative approaches that enhance our understanding of antibiotic pharmacology and facilitate more accurate predictions of treatment success, coupled with traditional pharmacology research, can be applied at the population level and to individual patients to improve outcomes.
AB - Antibiotic resistance presents an incessant threat to our drug armamentarium that necessitates novel approaches to therapy. Over the past several decades, investigation of pharmacokinetic and pharmacodynamic (PKPD) principles has substantially improved our understanding of the relationships between the antibiotic, pathogen, and infected patient. However, crucial gaps in our understanding of the pharmacology of antibacterials and their optimal use in the care of patients continue to exist; simply attaining antibiotic exposures that are considered adequate based on traditional targets can still result in treatment being unsuccessful and resistance proliferation for some infections. It is this salient paradox that points to key future directions for research in antibiotic therapeutics. This Personal View discusses six priority areas for antibiotic pharmacology research: (1) antibiotic-pathogen interactions, (2) antibiotic targets for combination therapy, (3) mechanistic models that describe the time-course of treatment response, (4) understanding and modelling of host response to infection, (5) personalised medicine through therapeutic drug management, and (6) application of these principles to support development of novel therapies. Innovative approaches that enhance our understanding of antibiotic pharmacology and facilitate more accurate predictions of treatment success, coupled with traditional pharmacology research, can be applied at the population level and to individual patients to improve outcomes.
UR - http://www.scopus.com/inward/record.url?scp=85139051493&partnerID=8YFLogxK
U2 - 10.1016/S2666-5247(22)00121-5
DO - 10.1016/S2666-5247(22)00121-5
M3 - Review Article
AN - SCOPUS:85139051493
SN - 2666-5247
VL - 3
SP - e795-e802
JO - The Lancet Microbe
JF - The Lancet Microbe
IS - 10
ER -
